AR024145A1 - Derivados de 5-fenil-pirimidina - Google Patents

Derivados de 5-fenil-pirimidina

Info

Publication number
AR024145A1
AR024145A1 ARP000102642A ARP000102642A AR024145A1 AR 024145 A1 AR024145 A1 AR 024145A1 AR P000102642 A ARP000102642 A AR P000102642A AR P000102642 A ARP000102642 A AR P000102642A AR 024145 A1 AR024145 A1 AR 024145A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
halogen
receptor
compounds
Prior art date
Application number
ARP000102642A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR024145A1 publication Critical patent/AR024145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Abstract

Compuestos de formula general (1) en donde: R1 es hidrogeno o halogeno; R2 es hidrogeno, halogeno, alquilo inferior o alcoxilo inferior; R3 es halogeno,trifluorometilo, alcoxilo inferior o alquilo inferior; R4 y R4 son independientemente entre sí, hidrogeno o alquilo inferior; R5 es alquilo inferior, alcoxiloinferior, amino, hidroxilo, hidroxialquilo inferior, -(CH2)n-piperazinilo, -(CH2)n-morfolinilo opcionalmente substituido con alquilo inferior,-(CH2)n+1-imidazolilo, -O-(CH2)n+1-morfolinilo,-O-(CH2)n+1-piperidinilo, alquilo inferior-sulfanilo, alquilo inferior-sulfonilo, bencilamino,-NH-(CH2)n+1N(R4)2, -(CH2)n-NH-(CH2)n+1N(R4)2, -(CH2)n+1N(R4)2, o -O-(CH2)n+1N(R4)2, en donde R4 es hidrogeno o alquilo inferior; R6 es hidrogeno; R2y R6 oR1 y R6 pueden ser juntamente con los dos átomos de C del anillo, -CH=CH-CH=CH-, con la condicion de que n para R1 sea 1; n es independientemente 0-2; yX es -C(O)N(R4)- o N(R4)C(O)-; y las sales de adicion ácida farmacéuticamente aceptables de los mismos. Los compuestos de formula (1) tienen una elevadaafinidad para el receptor de la NK-1. Son por lo tanto, de utilidad para el tratamiento de enfermedades que están relacionadas con este receptor.
ARP000102642A 1999-05-31 2000-05-29 Derivados de 5-fenil-pirimidina AR024145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31

Publications (1)

Publication Number Publication Date
AR024145A1 true AR024145A1 (es) 2002-09-04

Family

ID=8238270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102642A AR024145A1 (es) 1999-05-31 2000-05-29 Derivados de 5-fenil-pirimidina

Country Status (36)

Country Link
US (1) US6756380B1 (es)
EP (1) EP1187814B1 (es)
JP (1) JP3590591B2 (es)
KR (1) KR100478369B1 (es)
CN (1) CN1187338C (es)
AR (1) AR024145A1 (es)
AT (1) ATE273962T1 (es)
AU (1) AU769265B2 (es)
BR (1) BR0011097A (es)
CA (1) CA2375670C (es)
CO (1) CO5170529A1 (es)
CZ (1) CZ20014273A3 (es)
DE (1) DE60013127T2 (es)
DK (1) DK1187814T3 (es)
ES (1) ES2225144T3 (es)
GC (1) GC0000338A (es)
HK (1) HK1046411B (es)
HR (1) HRP20010867A2 (es)
HU (1) HU225016B1 (es)
IL (2) IL146519A0 (es)
JO (1) JO2308B1 (es)
MA (1) MA26794A1 (es)
MX (1) MXPA01011704A (es)
MY (1) MY136258A (es)
NO (1) NO321334B1 (es)
NZ (1) NZ515408A (es)
PE (1) PE20010203A1 (es)
PL (1) PL353492A1 (es)
PT (1) PT1187814E (es)
RU (1) RU2244710C2 (es)
SI (1) SI1187814T1 (es)
TR (1) TR200103460T2 (es)
TW (1) TWI263638B (es)
WO (1) WO2000073278A2 (es)
YU (1) YU85001A (es)
ZA (1) ZA200109496B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
CZ20024041A3 (cs) 2000-06-13 2003-04-16 Basf Aktiengesellschaft Fungicidní 5-fenyl substituované 2-(kyanamino) pyrimidiny
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
PL375263A1 (en) 2002-07-02 2005-11-28 F.Hoffmann-La Roche Ag 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
WO2005046604A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-hydrazone compounds
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
US7696202B2 (en) * 2004-11-10 2010-04-13 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
KR20170107536A (ko) 2015-01-30 2017-09-25 바스프 에스이 제초 페닐피리미딘
WO2018015180A1 (en) 2016-07-20 2018-01-25 Basf Se Herbicidal compositions comprising phenylpyrimidines
EP3487301A1 (en) 2016-07-25 2019-05-29 Basf Se Herbicidal pyrimidine compounds
WO2018019552A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
WO2018019555A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyrimidine compounds
WO2018019765A1 (en) 2016-07-27 2018-02-01 Basf Se Herbicidal pyrimidine compounds
WO2018019574A1 (en) 2016-07-28 2018-02-01 Basf Se Herbicidal pyrimidine compounds
CA3064513A1 (en) 2017-06-14 2018-12-20 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
DK3853219T3 (da) 2018-09-19 2023-10-09 Bayer Ag Herbicidt virksomme substituerede phenylpyrimidinhydrazider

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法

Also Published As

Publication number Publication date
EP1187814A2 (en) 2002-03-20
DE60013127T2 (de) 2005-09-08
HK1046411B (zh) 2005-05-27
DE60013127D1 (de) 2004-09-23
HUP0201527A2 (en) 2002-08-28
IL146519A0 (en) 2002-07-25
CA2375670A1 (en) 2000-12-07
CA2375670C (en) 2009-09-29
KR100478369B1 (ko) 2005-03-24
GC0000338A (en) 2007-03-31
BR0011097A (pt) 2002-03-19
SI1187814T1 (en) 2004-12-31
AU769265B2 (en) 2004-01-22
JO2308B1 (en) 2005-09-12
IL146519A (en) 2006-12-10
WO2000073278A2 (en) 2000-12-07
TR200103460T2 (tr) 2002-05-21
DK1187814T3 (da) 2004-12-20
PL353492A1 (en) 2003-11-17
PT1187814E (pt) 2004-10-29
NO321334B1 (no) 2006-04-24
PE20010203A1 (es) 2001-02-15
MY136258A (en) 2008-09-30
JP3590591B2 (ja) 2004-11-17
HU225016B1 (en) 2006-05-29
NO20015701L (no) 2001-11-22
KR20020003399A (ko) 2002-01-12
CN1353696A (zh) 2002-06-12
CO5170529A1 (es) 2002-06-27
US6756380B1 (en) 2004-06-29
HUP0201527A3 (en) 2005-01-28
NO20015701D0 (no) 2001-11-22
WO2000073278A3 (en) 2001-07-05
ZA200109496B (en) 2003-02-17
AU5070800A (en) 2000-12-18
CN1187338C (zh) 2005-02-02
RU2244710C2 (ru) 2005-01-20
YU85001A (sh) 2004-09-03
TWI263638B (en) 2006-10-11
HRP20010867A2 (en) 2003-04-30
MA26794A1 (fr) 2004-12-20
MXPA01011704A (es) 2002-05-14
CZ20014273A3 (cs) 2002-05-15
ATE273962T1 (de) 2004-09-15
ES2225144T3 (es) 2005-03-16
EP1187814B1 (en) 2004-08-18
HK1046411A1 (en) 2003-01-10
JP2003500477A (ja) 2003-01-07
NZ515408A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
AR024145A1 (es) Derivados de 5-fenil-pirimidina
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
HUP0402336A2 (hu) Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
HUP0103386A2 (hu) Kinazolinszármazékok alkalmazása JAK 3 inhibitor hatású gyógyszerkészítmények előállítására
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
HUP0400250A2 (hu) 5-HT6 és/vagy 5-HT7 szerotonin receptorok ligandumaként alkalmazott 5-halogén-triptamin-származékok, előállításuk és alkalmazásuk gyógyszerkészítmények előállítására
HUP0202049A2 (hu) Egyebek mellett osteoporosis kezelésére alkalmazható indolszármazékok
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
MY129224A (en) 4-phenyl-pyridine derivatives
DE3069813D1 (en) Pharmaceutical composition containing a diphenylhydantoin derivative, derivatives used and their preparation
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR024146A1 (es) Derivados de 4-fenil-pirimidina
ATE59632T1 (de) Dihydrodibenzocycloheptylidenethylamin-derivate
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması
KR970706261A (ko) 치료법에 유용한 퀴녹살린 유도체(quinoxaline derivatives useful in therapy)
HK1047586A1 (en) Process for the preparation of pyrazoloÄ1,5-bÜpyridazine derivatives.
DE69330601T2 (de) Serotoninergische ergolin derivate
TR200002831A2 (tr) Kinolin-4-İl türevleri I
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme

Legal Events

Date Code Title Description
FA Abandonment or withdrawal